MedPath

A study to evaluate the Safety, In-Use Tolerability and Efficacy of a test product in reducing acne and acne spots on the face.

Not Applicable
Completed
Registration Number
CTRI/2023/10/058218
Lead Sponsor
Himalaya Wellness Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
102
Inclusion Criteria

1)Subjects having good general health as determined by the Investigator on the basis of medical history. Subjects with acne-prone skin and with mild to moderate acne condition as per IGA scale and acne prone skin.

2)Subjects with oily skin having Sebumeter measurement > 180 (µg/cm2).

3)Female subjects of childbearing potential must have a negative urine pregnancy test performed on screening and enrolment visit.

4)Subjects who are not under any dermatologic treatment for acne and scar/ prescribed medications.

Exclusion Criteria

1)Subjects with drug induced acne as disclosed by subjects.

2)Subjects undergoing treatment for skin lightening or subjects using other marketed skin lightening products during the study period or in the past 6 weeks.

3)Subjects who are receiving topical or systemic treatments for acne or acne marks.

4)Subjects receiving medications (e.g., steroids or anti-histamines) which would compromise the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of acne severity (in terms of reducing acne) using Investigator global assessment (IGA) and counting of inflammatory and non-inflammatory lesions.Timepoint: Day 01 (before application to Day 29 (plus 2 days)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath